26th week of 2015 patent applcation highlights part 9 |
Patent application number | Title | Published |
20150174095 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VISUAL SYSTEM DISORDERS - The present invention relates to pharmaceutical compositions comprising D-serine transporter inhibitors which are proline analogues and therapeutic methods using such pharmaceutical compositions in methods for the treatment of visual system disorders and the enhancement of the visual function. | 2015-06-25 |
20150174096 | TOPICAL OPHTHALMOLOGICAL PHARMACEUTICAL COMPOSITION CONTAINING SUNITINIB - The present invention relates to topical ophthalmological pharmaceutical compositions containing sunitinib, a hydrate, solvate or pharmaceutically acceptable salt thereof or a polymorph thereof and its process of preparation and its use for treating ophthalmological disorders. | 2015-06-25 |
20150174097 | TREATING EWING'S SARCOMA AND EWS-FLI1 RELATED DISORDERS - The field relates to compositions and methods for treating Ewing's Sarcoma and other disorders related to EWS-FLI1. | 2015-06-25 |
20150174098 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS - Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention. | 2015-06-25 |
20150174099 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS - Disclosed herein are compositions and methods of treating osteoporosis, bone fracture, bone loss, and increasing bone density by administration of compounds of formula (I) | 2015-06-25 |
20150174100 | METHODS FOR THE TREATMENT OF PSORIATIC ARTHRITIS USING APREMILAST - Methods of treating, managing or preventing psoriatic arthritis are disclosed. Specific methods encompass the administration of apremilast, alone or in combination with a second active agent. | 2015-06-25 |
20150174101 | MELATONIN TABLET AND METHODS OF PREPARATION AND USE - The present invention provides a pharmaceutical composition for sublingual or buccal administration of actives with low to poor aqueous solubility, e.g. the indole hormone melatonin, which contains a solution of the active in a pharmaceutically acceptable solvent adsorbed or absorbed onto particles of a pharmaceutically acceptable carrier and methods of preparing and using the pharmaceutical composition. | 2015-06-25 |
20150174102 | ETHERS, SECONDARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT 2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO - The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT | 2015-06-25 |
20150174103 | UREA COMPOUNDS AND THEIR USE AS ENZYME INHIBITORS - A compound having the following structure: | 2015-06-25 |
20150174104 | SYSTEMS AND METHODS TO TREAT PAIN LOCALLY - Disclosed herein are systems and methods for contributing to the local treatment of pain. More specifically, the disclosed systems and methods contribute to the local treatment pain by inhibiting the NFκB family of transcription factors. | 2015-06-25 |
20150174105 | Ophthalmic Composition for Correcting Presbyopia - Ophthalmic composition for the correction of presbyopia. Composition consisting of 2% Pilocarpine, characterized by being diluted to 1% with sterile Balanced Salt Solution (BSS), obtaining 1% pilocarpine (2.5 ml)+bromfenac, 1.8 mgrs of bromfenac (2.5 ml)+sterile Balanced Salt Solution (BSS) (2.5 ml), finally obtaining eye drops of 7.5 ml. It is also possible to obtain a 1.5% and 2% pilocarpine. | 2015-06-25 |
20150174106 | Stabilized Amine-Containing Actives in Oral Film Compositions - The present invention relates to compositions relating to films containing active pharmaceutical agents. In particular, the present invention relates to methods and systems useful for stabilizing amine-containing actives for dispersion in a film product. | 2015-06-25 |
20150174107 | TRKB AGONISTS AND METHODS OF USE - Compounds and methods related to the activation of the TrkB receptor are provided. The methods include administering a 7,8-dihydroxyflavone derivative with modified flavone or heterocyclic ring to a subject in need thereof. Methods and compounds for the treatment of disorders including neurologic disorders, neuropsychiatric disorders, and metabolic disorders (e.g., obesity) are provided. | 2015-06-25 |
20150174108 | METHOD OF WEIGHT REDUCTION - The present disclosure relates generally to the use of methazolamide in therapy. The disclosure particularly relates to regulation of glucose homeostasis and reduction of body mass in patients suffering from or susceptible to diseases and associated conditions, in which undesirably high blood glucose levels are involved or implicated, such as diabetes, syndrome X, hyper-glycaemia, vascular disease and kidney disease. The present disclosure further relates to compounds and agents and compositions thereof for use in the treatment methods. | 2015-06-25 |
20150174109 | BERBERINE FORMULATIONS AND USES THEREOF - Pharmaceutical compositions comprising berberine for treatment of skin disorders and methods of use thereof. | 2015-06-25 |
20150174110 | NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE - The present disclosure relates to novel compounds, methods, and compositions capable of inhibiting HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF). | 2015-06-25 |
20150174111 | INSULIN INDEPENDENCE AMONG PATIENTS WITH DIABETES UTILIZING A PPI IN COMBINATION WITH AN IMMUNE TOLERANCE AGENT - To date, no immune tolerance agent or combination of immune tolerance agents has been able to sustain insulin-independence among type 1 diabetes patients. This patent provides methods and pharmaceutical compositions for providing insulin independence among newly diagnosed and existing type 1 diabetes. Methods include utilization of PPIs, which increase gastrin resulting in the transformation of human ductal tissue into insulin-secreting new beta cells, used in combination with an immune tolerance agent to protect the new insulin-producing beta cells generated by the PPI from immune destruction. Compositions and methods are provided for beta cell generation therapy comprising at least one member from a group of PPIs with formulations selected from immune tolerance agents, when used in combination result in insulin-independence among new and existing type 1 patients whom currently require insulin to sustain life. Compositions and methods are provided for insulin-independence among type 2 patients using PPIs when combined with therapeutic agents utilized for the treatment of type 2 diabetes. | 2015-06-25 |
20150174112 | COMPOSITIONS FOR TREATING FRAGILE X AND OTHER DISORDERS METHODS OF USE THEREOF, AND SCREENING FOR COMPOUNDS FOR FRAGILE X AND OTHER DISORDERS - Methods of screening compounds, active compositions, pharmaceutical compositions, methods of treating disorders, methods of preventing disorders, and kits to screen a library of compounds, are disclosed. | 2015-06-25 |
20150174113 | SUBSTITUTED AMINOINDANE- AND AMINOTETRALINECARBOXYLIC ACIDS AND THE USE THEREOF - The present application relates to novel substituted aminoindane- and aminotetralinecarboxylic acids, to processes for preparation thereof, to the use thereof for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of cardiovascular and cardiopulmonary diseases. | 2015-06-25 |
20150174114 | METHODS FOR THE TREATMENT OF NON-HODGKIN'S LYMPHOMAS USING LENALIDOMIDE, AND GENE AND PROTEIN BIOMARKERS AS A PREDICTOR - Methods of treating or managing specific cancers, including non-Hodgkin's lymphoma, by the administration of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Methods of using gene and protein biomarkers as a predictor of non-Hodgkin's lymphoma response to treatment with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione are also disclosed. | 2015-06-25 |
20150174115 | HEPATITIS B ANTIVIRAL AGENTS - Provided herein are compounds useful for the treatment of HBV infection in man. | 2015-06-25 |
20150174116 | TRANSMUCOSAL DRUG DELIVERY SYSTEM - Disclosed are preparations and formulations of high thermodynamic activity lipophilic associations (LA), in which there is pairing between an ionizable pharmaceutical agent and a lipophilic species having ionic characteristics opposite to that of the pharmaceutical agent. Such lipophilic associations manifest high thermodynamic activity, as evidenced by their being predominantly in a liquid phase at room temperature or solvated in a lower-than-water dielectric solvent. Further the pharmaceutical agent being solubilized means that dissolution is not rate limiting to transmucosal absorption. This LA or LA-solvate is formulated into a low dielectric dosage form, from whence, upon the dosage form's hydration, the pharmaceutical agent is driven through the mucosal tissue and into systemic circulation. The invention therefore provides an enhanced transmucosal drug delivery system for ionizable pharmaceutical agents at or near physiological pH. | 2015-06-25 |
20150174117 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT - An anti-HIV agent containing, as an active ingredient, a 4-oxoquinoline compound represented by the following formula [I] | 2015-06-25 |
20150174118 | USE OF LAQUINIMOD TO DELAY HUNTINGTON'S DISEASE PROGRESSION - The subject invention provides methods of treating or delaying disease progression in a subject afflicted with Huntington's disease (HD) comprising administering to the subject 0.5-1.5 mg/day laquinimod. The subject invention also provides packages, therapeutic packages and pharmaceutical compositions, comprising one or more unit doses of 0.5-1.5 mg laquinimod for treating or delaying disease progression in a subject afflicted with HD. Also disclosed is use of laquinimod in the manufacture of a medicament comprising one or more unit doses of 0.5-1.5 mg laquinimod for use in treating or delaying disease progression in a subject afflicted HD. | 2015-06-25 |
20150174119 | COMPOSITIONS AND METHODS FOR TREATMENT - The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists. | 2015-06-25 |
20150174120 | MULTIDOSE PACKAGE, COURSE AND METHOD OF TREATMENT FOR DELIVERING PREDETERMINED MULTIPLE DOSES OF A PHARMACEUTICAL - A multidose package containing an imiquimod formulation suitable for treating topical conditions includes: a) a dispensing aperture for dispensing the formulation from the package; b) a reservoir containing sufficient formulation to provide two or more doses; c) a metered dosage element for measuring a predetermined dose of the formulation, the element including an inlet from the reservoir and an outlet to the dispensing aperture; and d) an actuating element operating the dosage element so the predetermined dose is delivered to the dispensing aperture; wherein the dose is dispensed without microbial or other contamination or degradation of the formulation in reservoir. A corresponding course of treatment for various maladies includes providing a multidose package containing an imiquimod formulation suitable for the treatment. A corresponding method of treatment of diseases with multiple doses of an imiquimod formulation includes multiple doses provided by a multidose package. | 2015-06-25 |
20150174121 | CONTROLLED RELEASE HYDROCODONE FORMULATIONS - A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C | 2015-06-25 |
20150174123 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF REPERFUSION INJURY - A method of reducing reperfusion injury in mammalian tissue comprising contacting the tissue with a protein phosphatase 2A (PP2A) inhibitor having the structure: | 2015-06-25 |
20150174124 | CRYSTALLINE FORMS OF TRYOSINE KINASE INHIBITORS AND THEIR SALTS - The invention relates to various polymorphic forms and amorphous form of sodium 4-((3-(4-cyclohexylpiperazin-1-yl)-6-oxo-6H-anthra[1,9-cd]isoxazol-5-yl)amino)benzate, including the polymorphic form A, mixtures of the polymorphs, process for the preparation thereof and the use thereof in a pharmaceutical composition containing thereof. | 2015-06-25 |
20150174125 | 5-HT1A RECEPTOR SUBTYPE AGONIST - The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT | 2015-06-25 |
20150174126 | Pharmaceutical combination - The present invention relates to a pharmaceutical combination which may be useful for the treatment of diseases which involve cell proliferation, which involve migration or apoptosis of myeloma cells, which involve angiogenesis or which involve fibrosis. The invention also relates to a method for the treatment of said diseases, comprising simultaneous, separate or sequential administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations. | 2015-06-25 |
20150174127 | Pyrrolopyrazine-Spirocyclic piperidine amides as modulators of ion channels - The invention relates to pyrrolopyrazine-spirocyclic piperidine amide compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders. | 2015-06-25 |
20150174128 | HETEROARYL COMPOUNDS AND USES THEREOF - The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | 2015-06-25 |
20150174129 | SUBSTITUTED 2-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS - The present invention is directed to compounds of Formula I: | 2015-06-25 |
20150174130 | COMPOSITIONS AND METHODS FOR TREATING MICROBIAL INFECTIONS - Embodiments of the presently-disclosed subject matter include activators of HssRS that induce endogenous heme biosynthesis by perturbing central metabolism. These molecules are toxic to fermenting | 2015-06-25 |
20150174131 | NOVEL KINASE MODULATORS - The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them. | 2015-06-25 |
20150174132 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS - The invention relates to a method for treating B-cell regulated autoimmune disorders using compounds that modulate the activity of c-Rel. | 2015-06-25 |
20150174133 | NITROGEN CONTAINING COMPOUNDS - Compounds of Formula (I), their preparation and use in preventing or treating bacterial infection is disclosed. | 2015-06-25 |
20150174134 | METHOD FOR INHIBITING TOPOISOMERASE II - The present invention relates to compounds that inhibit the activity of Hsp90 and inhibit topoisomerase II. | 2015-06-25 |
20150174135 | FLAVANOID COMPOUNDS AND PROCESS FOR PREPARATION THEREOF - The present invention relates to flavanoid compounds of general formula (X | 2015-06-25 |
20150174136 | SUBSTITUTED BENZENE COMPOUNDS - The present invention relates to substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes. | 2015-06-25 |
20150174137 | COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS - The present invention relates to methods for treating a microbial infection comprising treating the infected tissue with a composition comprising a quinolone such as finafloxacin and a divalent cation such as magnesium. The present invention also relates to antimicrobial compositions comprising a quinolone such as finafloxacin and a divalent cation such as magnesium. | 2015-06-25 |
20150174138 | DIAGNOSTIC AND TREATMENT METHODS IN SUBJECTS HAVING OR AT RISK OF DEVELOPING RESISTANCE TO CANCER THERAPY - The invention relates to methods of treatment and diagnosis of subjects with cancer. In some aspects, the invention relates to methods of treatment and diagnosis of subjects with cancer, wherein the cancer is characterized by a Notch pathway activation mutation or by resistance to a Notch pathway inhibitor. | 2015-06-25 |
20150174139 | Misoprostol Composition - The present invention relates to the use of misoprostol for the induction of labour in a pregnant female, and in particular to the use of a sustained delivery device or insert containing substantially 200 μg misoprostol for intravaginal use. The use encompasses methods of therapy as well as compositions for use in such methods. | 2015-06-25 |
20150174140 | METHOD FOR ON-DEMAND CONTRACEPTION - The invention relates to a method for on-demand contraception, which method comprises administering a progestogen agent or progesterone receptor modulator, such as 17a-acetoxy-11b-(4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal acetate) in a woman, within 72 hours before an intercourse or within 120 hours after the intercourse. | 2015-06-25 |
20150174141 | METHOD FOR POST COITAL CONTRACEPTION IN OVERWEIGHT OR OBESE FEMALE SUBJECTS USING ULIPRISTAL ACETATE - The invention provides a method for providing post coital contraception in a female subject, comprising providing the subject with a therapeutically effective amount of ulipristal acetate, wherein the female subject is overweight or obese. | 2015-06-25 |
20150174142 | MANAGEMENT OF BREAKTHROUGH BLEEDING IN EXTENDED HORMONAL CONTRACEPTIVE REGIMENS - The present invention relates to a flexible extended use regimen for a hormonal contraceptive useful to manage bleeding problems associated with fixed extended use of hormonal contraceptives and to a pharmaceutical package containing the respective hormonal contraceptive. | 2015-06-25 |
20150174143 | NOVEL PRODRUGS OF C-17-HETEROARYL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS: SYNTHESIS, IN VITRO BIOLOGICAL ACTIVITIES, PHARMACOKINETICS AND ANTITUMOR ACTIVITY - Prodrugs of steroidal C-17 benzoazoles, pyrimidinoazoles (az-abenzoazoles) and diazines. Methods of synthesis are also described, whereby a prodrug group is substituted for a functional group at A ring portion of the ABC ring structure of the steroid. Suitable pro-drug groups include amino acid groups, succinate groups, phosphate groups, or sulfamate groups. The prodrugs of the disclosed compounds allow for improved oral bioavailability of the compounds that are inhibitors of human CYP 17 enzyme as well as potent antagonists of both wild type and mutant androgen receptors (AR). The compounds and the corresponding prodrugs are useful for the treatment of conditions such as human prostate cancer, breast cancer, and prostate hyperplasia. | 2015-06-25 |
20150174144 | TETRACYCLINE COMPOUNDS FOR TREATING NEURODEGENERATIVE DISORDERS - Tetracycline compounds for treating neurodegenerative disorders are disclosed herein. Also disclosed is a pharmaceutical composition comprising the tetracycline compounds, and a method for treating, preventing, or ameliorating neurodegenerative disorders or inflammation in a subject by administering the tetracycline compounds or a pharmaceutical composition thereof, either alone or in combination with a second therapeutic agent. | 2015-06-25 |
20150174145 | Pharmaceutical compounds with the structure of ionic salts with antibiotic and anticancer action - Pharmaceutical compounds were prepared as ionic salts, liquid under 150° C., consisting in a cation containing Alkyl and/or Phenyl groups and an anion consisting in an existing pharmaceutical antibiotica, whose biological properties are strongly enhanced by the cation, concerning elimination of resistance of bacteria and surprisingly also anticancer action. | 2015-06-25 |
20150174146 | ANGIOTENSIN CONVERTING ENZYME INHIBITORS FOR TREATING OPTIC NEUROPATHY OR CONGENITAL OPTIC ATROPHY - The present invention relates to an ophthalmic composition comprising at least one angiotensin converting enzyme (ACE) inhibitor and a pharmaceutically acceptable vehicle for use as an ophthalmic neuroprotector in treating an optic neuropathy or congenital optic atrophy. | 2015-06-25 |
20150174147 | UNITARY PHARMACEUTICAL DOSAGE FORM - In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation. | 2015-06-25 |
20150174148 | USE OF NICOTINAMIDE RIBOSIDE TO TREAT HEARING LOSS - The invention provides a method of preventing or treating hearing loss in a mammal in need thereof. The method involves administering to the mammal an agent that increases intracellular NAD+ in the mammal. The invention also provides a method of determining if a compound acts as a neuroprotective agent. | 2015-06-25 |
20150174149 | COMPOSITIONS INCLUDING TRICIRIBINE AND METHODS OF USE THEREOF - This invention encompasses combination therapies including TCN, TCN-P, TCN-PM and/or related compounds and one or more additional anti-cancer agents, for example, taxanes a molecule that modulates the HER2/neu (erbB2) receptor, anthracyclin compounds, epidermal growth factor receptor inhibitor compounds, one or more platinum compounds and bortezomib and derivatives thereof and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation. | 2015-06-25 |
20150174150 | Compositions and Methods for Treating Alzheimer's Disease and Other Tauopathies - Compounds, pharmaceutical compositions, and methods of using such compounds and compositions to treat or prevent Alzheimer's disease and related tauopathies through the inhibition of USP-9X and/or enhancement of SCF(β-TrCP). | 2015-06-25 |
20150174151 | COMPOSITION OF NOVEL CARBOHYDRATE DRUG FOR TREATMENT OF HUMAN DISEASES - Aspects of the invention provide compositions for use in the treatment galectin-dependent diseases. In particular, compositions comprising a selectively depolymerized, branched galactoarabino-rhamnogalacturonate whose backbone is predominantly comprised of 1,4-linked galacturonic acid (GalA) moieties, with a lesser backbone composition of alternating 1,4-linked GalA and 1,2-linked rhamnose (Rha), which in-turn is linked to any number of side chains, including predominantly 1,4-b-D-galactose (Gal) and 1,5-a-L-arabinose (Ara) residues. | 2015-06-25 |
20150174152 | FAT BINDER OBTAINED FROM BIOMASS RESULTING FROM BEER PRODUCTION - The present invention provides a polysaccharide rich composition comprising beta-glucan, chitin and chitosan, extracted from the cell wall of | 2015-06-25 |
20150174153 | CHITOSAN HYDROGEL FOR REPAIRING NERVE TISSUE - The present invention relates to chitosan hydrogel microparticles of a median size d50 comprised between 1 and 500 μm (obtained from a number distribution), the chitosan having a degree of acetylation of less than equal to 20% and its concentration in the hydrogel being comprised between 0.25 and 5% by weight based on a total weight of the hydrogel, for use in neuron regeneration and/or in the repair of the nervous system, advantageously of the central nervous system, and/or in the grafting of neurons and/or in the treatment of neurodegenerative diseases and/or in the treatment of paralyses. | 2015-06-25 |
20150174154 | SKIN AND HAIR REGENERATION USING POLYSACCHARIDE-BASED HYDROGELS - Methods for promoting skin regeneration, promoting hair follicle regeneration, and reducing scarring by topically administering polysaccharide-based hydrogel compositions to injured skin are presented. | 2015-06-25 |
20150174155 | MODIFIED IMMUNE-MODULATING PARTICLES - The current invention involves the surprising finding that when carboxylated particles, such as carboxylated polystyrene, PLGA, or diamond particles are administered to subjects, inflammatory immune responses are ameliorated. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same carboxylated particles. | 2015-06-25 |
20150174156 | Controllably Degradable Compositions and Methods - Methods for treating, adhering, or sealing biological tissue are provided. The methods include combining solutions containing a polymer component and a dendrimer component capable of reacting with each other, and at least one of the components includes a substituent capable of photoreversible dimerization that can be reversibly dimerized. Drug delivery compositions and kits containing these two components also are provided. | 2015-06-25 |
20150174157 | INHALED NO DONOR PIPERAZINYL DERIVATIVE PREVENTING ALLERGIC PULMONARY VASCULAR AND BRONCHIAL INFLAMMATION BY REDUCING VEGF AND RESTORING eNOS IN HYPOXIC PULMONARY ARTERY - A method for treating a disease is disclosed. The method includes steps of providing a subject in need thereof; and administering one selected from a group consisting of Piperazinyl Analogs and Piperazinyl Complex Analogs compound represented by formula II or formula III, a pharmaceutically acceptable salts thereof; and a pharmaceutical composition thereof to the subject in a dosage between 1 and 5.0 milligrams per kilogram of body weight, in a liquid mist, dry powder or aerosolized formulation. | 2015-06-25 |
20150174158 | INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES - A method of treating a human subject which is effected by intermittent inhalation of gaseous nitric oxide at a concentration of at least 160 ppm is disclosed. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract. The disclosed method can be effected while monitoring one or more of on-site and off-site parameters such as vital signs, methemoglobin levels, pulmonary function parameters, blood chemistry and hematological parameters, blood coagulation parameters, inflammatory marker levels, liver and kidney function parameters and vascular endothelial activation parameters, such that no substantial deviation from a baseline in seen in one or more of the monitored parameters. | 2015-06-25 |
20150174159 | GAS CONDITIONING - A method for reducing or preventing mesothelial cell damage by mixing a carrier gas and between 1 volume percent and 29 volume percent of nitrous oxide gas (N | 2015-06-25 |
20150174160 | METHODS FOR TREATING, DIAGNOSING AND/OR MONITORING PROGRESSION OF OXO ASSOCIATED STATES - Disclosed are methods for diagnosing, treating and/or monitoring clinical progression associated states, e.g., hypermetabolic associated states or sepsis associated states. | 2015-06-25 |
20150174161 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASES ASSOCIATED WITH OXIDATIVE STRESS - Methods and compositions for treating various indications by lessening oxidative stress in a patient are provided. A pharmaceutical composition comprises between about 0.001% to about 10.0%), or more specifically between about 0.015% to about 5%, sodium iodine or catalase by weight. The iodine ion or the catalase dissociates hydrogen peroxide into water and molecular oxygen to interrupt biological events that result in negative side effects. The pharmaceutical composition further comprises in some cases a reducing agent or various carrier materials. The pharmaceutical composition is in some cases formulated for a variety of delivery methods. | 2015-06-25 |
20150174162 | EXERCISE PHYSIOLOGY ELECTROLYTE MANAGEMENT - The present invention provides methods for maintaining electrolyte balance and hydration in a person habituated to strenuous physical exertion by assaying perspiration generated by the person under conditions of strenuous physical exertion to determine the volume of perspiration as a function of duration of exertion and the sodium content of the person's perspiration during strenuous physical exertion The person is assigned to one of a plurality of groups of individuals, each group differing in the amount of sodium present in the perspiration and having a unique rehydration solution. The invention also provides for a set rehydration compositions, each member of the set comprising sodium and chloride differing from the weight percentage of sodium in the other members of the set and each member of the set being perceptually labeled to distinguish that member from the other members of the set by one of the human senses. | 2015-06-25 |
20150174163 | METHODS FOR IDENTIFYING AND INHIBITING GROWTH OF CHEMOTHERAPEUTIC-RESISTANT CANCERS - The present invention is a biomarker of chemotherapeutic drug-resistant cancer stem cells and a method of inhibiting the growth of drug-resistant cancer stem cells. In one embodiment the cancer stem cells are testicular cancer germ cells. In another embodiment the present invention is a method of overcoming drug resistance in cancer treatment where the combination of low dose decitabine and administration of a chemotherapeutic drug to which cancer cells were resistant results in successful cancer treatment. | 2015-06-25 |
20150174164 | NUTRITIONAL SUPPLEMENT CONTAINING PHOSPHOLIPID-DHA DERIVED FROM EGGS - Described herein are manufactured dietary supplements that contain a phospholipid extract derived from eggs, where the extract contains phospholipid-docosahexanoic acid derived from eggs, folate, vitamin D, vitamin B6, vitamin B12, vitamin C, calcium, iron, N-Acytl-L-Cysteine, iodine, and magnesium. | 2015-06-25 |
20150174165 | INGESTIBLE CANKER SORE TREATMENT - A treatment and prevention formulation for canker sores of the oral cavity including an aqueous alkaline solution having at least three B vitamins and either zinc (provided as Zn (II) EDTA alkali metal salt) or iron (provided as Fe (II) EDTA disodium salt) mixed therein and administered to a target area by a spray container. The vitamins are B | 2015-06-25 |
20150174166 | Compositions for Cellular Restoration and Methods of Making and Using Same - A method comprising obtaining a first cell sample from a first subject; obtaining a second cell sample from a second subject; culturing the first cell sample in the presence of at least a portion of a culture media of the second cell sample for a time period ranging from about 24 hours to about 6 weeks to produce a restoring composition; and contacting the restoring composition with the second cell sample for a period of time ranging from about 24 hours to about 6 weeks to produce a restored composition. | 2015-06-25 |
20150174167 | THERAPEUTIC USES OF ALLOGENEIC MYELOID PROGENITOR CELLS - Myeloid function is enhanced by transplantation or infusion of allogeneic myeloid progenitor cells, including CMP, GMP, MEP and MKP cell subsets. Myeloid progenitors ameliorate sequelae of anemia and thrombocytopenia, and can prevent or treat gastrointestinal mucositis associated with chemotherapy, radiotherapy, and the like. The transplantation or infusion may be performed in the absence of HLA typing, and the cells may be mismatched at one or more Class I HLA loci. The transplantation may provide for treatment of ongoing disease, or prevention of disease in high risk patients. | 2015-06-25 |
20150174168 | Acellular Pro-Tolerogenic Compositions and Process for Making Same - This invention relates to pro-tolerogenic preparations capable of increasing the level of regulatory T cells (Treg) and/or decreasing the level of pro-inflammatory T cells (Th17) to induce anergy or immune tolerance. The pro-tolerogenic preparation is enriched in at least one species of miRNAs and is obtained by contacting two allogeneic leukocyte populations wherein at least one of the two populations is modified with a low-immunogenic biocompatible polymer. Acellular pro-tolerogenic compositions, process for making such composition as well as therapeutic uses of such compositions are also provided. | 2015-06-25 |
20150174169 | DELIVERY METHODS AND COMPOSITIONS FOR NUCLEASE-MEDIATED GENOME ENGINEERING IN HEMATOPOIETIC STEM CELLS - The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a hematopoietic cell. | 2015-06-25 |
20150174170 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND ALLEVIATION OF BONE AND CARTILAGE DISEASES OR INJURIES AND HAIR LOSS - The present invention provides pharmaceutical compositions, and methods of preparation and use for the treatment, prevention or alleviation of bone and cartilage diseases or injuries and hair loss. The present invention discloses a method and a pharmaceutical composition comprising mesenchymal stem cells, platelets, activating factors and scaffolding materials for the treatment, prevention, or alleviation of bone diseases, bone injuries or hair loss, and a method and a pharmaceutical composition further comprising dexamethasone for the treatment, prevention, or alleviation of cartilage diseases or injuries. | 2015-06-25 |
20150174171 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND ALLEVIATION OF BONE AND CARTILAGE DISEASES OR INJURIES AND HAIR LOSS - The present invention provides pharmaceutical compositions, and methods of preparation and use for the treatment, prevention or alleviation of bone and cartilage diseases or injuries and hair loss. The present invention discloses a method and a pharmaceutical composition comprising mesenchymal stem cells, platelets, activating factors and scaffolding materials for the treatment, prevention, or alleviation of bone diseases, bone injuries or hair loss, and a method and a pharmaceutical composition further comprising dexamethasone for the treatment, prevention, or alleviation of cartilage diseases or injuries. | 2015-06-25 |
20150174172 | COMPOSITIONS AND METHODS FOR REDUCING FREQUENCY AND/OR SEVERITY OF HEADACHE - In one embodiment, the present invention relates to a method for reducing the frequency and/or severity of headache in a subject comprising administering to the subject a composition comprising the stromal vascular fraction or stromal cells of adipose tissue. In another embodiment, the present invention relates to a method for reducing the frequency and/or severity of headache in a subject comprising administering to the subject a composition compositing bone marrow. In another embodiment, the present invention relates to a method for reducing the frequency or severity of headache in a subject comprising administering to the subject a composition comprising adult stem cells. | 2015-06-25 |
20150174173 | STEM CELL TREATMENT FOR RADIATION EXPOSURE - The invention provides adult pluripotent stem cells (PSC) for treatment or prophylaxis for radiological exposure. In an embodiment of the invention, the cells are very small embryonic like stem cells (VSELs). The VSELs can be used to rescue the hematopoietic and immune systems of individuals suffering from the delayed effects of acute radiation syndrome (ARS). | 2015-06-25 |
20150174174 | Placental Stem Cells Derived From Post-Partum Mammalian Placenta, And Uses And Methods Of Treatment Using Said Cells - The present invention provides compositions and methods of using placental stem cells that originate from a post-partum placenta with conventional cord blood compositions or other stem or progenitor cells. The placental stem cells can be used alone or in a mixture with other stem cell populations. In accordance with the present invention, the placental stem cells may be mixed with other stem cell populations, including but not limited to, umbilical cord blood, fetal and neonatal hematopoietic stem cells and progenitor cells, human stem cells and progenitor cells derived from bone marrow. The placental stem cells and the mixed populations of placental stem cells and stem cells have a multitude of uses and applications, including but not limited to, therapeutic uses for transplantation and treatment and prevention of disease, and diagnostic and research uses. | 2015-06-25 |
20150174175 | METHOD FOR PRODUCING OYSTER MEAT ESSENCE CONTAINING LARGE AMOUNT OF ANTIOXIDANTS HAVING HIGH ANTIOXIDATIVE POWER AND HIGH ORAC VALUE - To provide a method for producing an oyster meat essence that more amply incorporates an antioxidant substance with high ORAC value as follows. A portion of an oyster meat extract more amply incorporating an antioxidant substance with high ORAC value is selected. An extraction method that allows incorporating further large amount of antioxidant substance with high ORAC value is employed. The beneficial oyster meat extract can be efficiently extracted in large amounts. | 2015-06-25 |
20150174176 | PREPARATION AND METHOD FOR THE PROPHYLAXIS AND TREATMENT OF OSTEOPOROSIS AND BONE FRACTURES - The method for preventing and treating osteoporosis and bone fractures and the preparation for preventing and treating osteoporosis and bone fractures relates to medicine, in particular to agents for the treatment and prevention of conditions associated with various forms of osteoporosis. The method is characterised in that it involves taking between 10 mg and 1000 mg per day of drone brood, between 50 IU and 1,000,000 IU per day of vitamin D or vitamins of this group and/or the active metabolites thereof, and between 25 mg and 3000 mg per day of a calcium compound, so as to be simultaneously supplied to the body daily, and the preparation composed of between 10 mg and 1000 mg of drone brood, between 50 IU and 1,000,000 IU of vitamin D or vitamins of this group and/or the active metabolites thereof and between 25 mg and 3000 mg of a calcium compound, can be in powder, tablet or capsule form. Implementing the invention provides for the achievement of the technical result stated by the author, which makes it possible to eliminate or reduce the mineralisation imbalance of various bone tissue segments. The use of the claimed agent strengthens the mechanism for uniformly restoring bone mineral density, the use of drone brood in combination with vitamin D aims to provide for additional strength in remodelling injured bone tissue segments and for bone tissue retention by maintaining androgen levels. | 2015-06-25 |
20150174177 | PROBIOTIC AND POLYPHENOL AGAINST NEURODEGENERATION - The present invention relates to a composition comprising the probiotic strain | 2015-06-25 |
20150174178 | Method and System for Prevention and Treatment of Allergic and Inflammatory Diseases - A method and system for exposing an expectant mother to a mixture of farm derived manure-containing soil to reduce the chances her baby will suffer allergies. City dwelling expectant mothers are exposed to immunologic agents and allergens in a fashion (e.g., via exposure to farm animal manure-containing soils) that charges their immune system and that of their fetus(es) so that their babies, once born, are provided with immunity against a variety of autoimmune diseases, including allergies commonly and increasingly experienced in modern urban environments. | 2015-06-25 |
20150174179 | SYNBIOTIC MIXTURE - This invention relates to a preparation comprising a probiotic bacterial strain and a prebiotic mixture comprising 5-70 wt % of at least one N-acetylated oligosaccharide selected from the group consisting of GalNAcα1-3Gal β1-4Glc, Gal β1-6GalNacα1-3Gal β1-4Glc and combinations thereof, 20-95 wt % of at least one neutral oligosaccharide selected from the group consisting of Galβ1-6Gal, Galβ1-6Galβ1-4Glc, Galβ1-6Galβ1-6Glc, Galβ1-3Galβ1-3Glc, Galβ1-3Galβ1-4Glc, Galβ1-6Galβ1-6Galβ1-4Glc, Galβ1-6Galβ1-3Galβ1-4Glc, Galβ1-3Galβ1-6Galβ1-4Glc, Galβ1-3Galβ1-3Galβ1-4Glc and combinations thereof and 2-50 wt % of at least one sialylated oligosaccharide selected from the group consisting of NeuAcα2-3Galβ1-4Glc, NeuAcα2-6Galβ1-4Glc and combinations thereof. The invention extends to food products comprising said preparation and to the use of the preparation in the prevention and treatment of infections. | 2015-06-25 |
20150174180 | SELECTING, PRODUCING, AND FEEDING WHOLE ALGAE AS A FEED SUPPLEMENT FOR CATTLE AND BISON TO PRODUCE MEAT HIGH IN OMEGA 3'S FOR HUMAN HEALTH - The present invention is a system and method for creating and using algae as a food supplement for cattle and buffalo thereby providing a desirable food supplement for cattle and buffalo wherein the meat and fat produced has increased specific Omega-3 polyunsaturated fatty acids for a product, which imparts a healthier cardiovascular or healthier central nervous system. | 2015-06-25 |
20150174181 | HERBAL EXTRACT AND A METHOD OF TREATING LUNG TUMOR THEREOF - The invention discloses an herbal extract of treating lung tumor. The herbal extract comprises | 2015-06-25 |
20150174182 | PRE MOISTENED WIPES FOR USE IN TREATING ANAL RECTAL IRRITATIONS AND DISORDERS - Many people who suffer from anal rectal discomfort and disorders need fibrous sheet materials which are pre-moistened with a solution for improved cleansing without excessive skin irritation. The invention particularly concerns wet wipes, such as anal-rectal wipes, which comprises a solution comprising hamamelis water or witch hazel, to effectively treat anal-rectal disorders. | 2015-06-25 |
20150174183 | METHODS AND POMEGRANATE EXTRACT COMPOSITION FOR TREATING DIABETES RELATED ATHEROSCLEROTIC COMPLICATIONS IN HUMANS - One or more embodiments of the invention are directed to methods of using pomegranate extracts for treating diabetes related atherosclerotic complications in humans. The methods comprise the step of administering to the patients a composition comprising a therapeutically effective amount of an extract from pomegranate. | 2015-06-25 |
20150174184 | USE OF TERMINALIA CHEBULA EXTRACT FOR TREATMENT OF OSTEOARTHRITIS - The present invention provides an optimized and/or enriched hydrolyzable tannoid blend derived from | 2015-06-25 |
20150174185 | VIRAL TRAPPERS - Viral trappers is our invention consisting of an extract of | 2015-06-25 |
20150174186 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING STAT3-MEDIATED DISEASE, COMPRISING SALVIA PLEBEIA R. BR. EXTRACT OR FRACTION THEREOF AS ACTIVE INGREDIENT - The present invention relates to a pharmaceutical composition for preventing or treating STAT3-mediated diseases, comprising a | 2015-06-25 |
20150174187 | Topical Treatment Compositions Comprising Benzoin and Olive Fruit Extract - Disclosed are treatment compositions adapted for application to mammalian skin, which treatment compositions are effective initiators for the generation of human keratinocytes on or within the treated skin, particularly in the locus of the skin wherein the treatment composition has been applied, which treatment composition comprises benzoin and an olive oil extract which contains hydroxytyrosol and/or hydroxytyrosol. In certain preferred embodiments the benzoin and the olive oil extract and/or hydroxytyrosol are microencapsulated. | 2015-06-25 |
20150174188 | METHODS FOR INHIBITING ADVANCED GLYCATION END PRODUCT PRODUCTION, INHIBITING FIBROBLAST APOPTOSIS, AND/OR PROMOTING HUMAN FIBROBLAST-COLLAGEN GRATING FORMULATION USING CHERRY BLOSSOM AND CHERRY LEAF EXTRACT - Disclosed is an AGE production inhibitor or the like, which effectively inhibits the production of an advanced glycation end product (AGE), while having improved biological safety. Specifically disclosed is an AGE production inhibitor or the like, which contains en extract of cherry tree (preferably blossoms or leaves thereof) and/or a processed product of the extract as an active substance. The AGE production inhibitor or the like contains, as an active substance, at least one compound that is selected from among 1-O-(E)-Caffeoyl-β-D-glucopyranoside, 1-O-(E)-Coumaroyl-β-D-glucopyranoside, 1-O-(E)-Cinnamoyl-β-D-glucopyranoside, Kaempferol 3-O-β-D-glucopyranoside, Quercetin 3-O-β-D-glucopyranoside, Kaempferol 3-O-(6″-malony)-β-D-glucopyranoside, and Quercetin 3-O-(6″-malony)-β-D-glucopyranoside. | 2015-06-25 |
20150174189 | USE OF PHARMACEUTICAL COMPOSITIONS IN PREPARING PHARMACEUTICALS FOR TREATING DIABETIC ULCER - The use of pharmaceutical compositions in preparing pharmaceuticals for treating diabetic ulcer in limb or on body surface, or in preparing medical dressing. The pharmaceutical compositions consist of (A) 3 to 15% by weight of edible beeswax and (B) 85 to 97% by weight of sesame oil extract of | 2015-06-25 |
20150174190 | Formulation Against General, Physical, And/Or Mental Fatigue - This patent presents a formulation that safely and effectively decreases the feeling of fatigue in treated individuals. Specifically, the natural formulation decreases the feeling of general fatigue, the feeling of physical fatigue, and the feeling of mental fatigue. | 2015-06-25 |
20150174191 | PHARMACEUTICAL COMPOSITION FOR TREATING HYPERPROLIFERATIVE DISEASES - The present invention relates to the field of biotechnology and medicine, in particular to a pharmaceutical composition having an antiproliferative activity and comprising an chimeric peptide and to a method of treating oncologic diseases, which includes introducing the chimerical peptide into a mammal requiring such treatment. The objective of the of invention is the development of a preparation that effectively penetrates the target cells and has a high cytostatic and cytotoxic activity. | 2015-06-25 |
20150174192 | PEA PROTEIN PEPTIDES WITH ANTI HELICOBACTER PYLORI ACTIVITY - The invention relates to a composition comprising pea protein hydrolysate for the treatment and/or prevention of infection by gastrointestinal pathogens, in particular | 2015-06-25 |
20150174193 | AGENTS FOR TREATING CYSTIC FIBROSIS - The present invention relates to compositions comprising cationic polymers and their use in treating inflammatory lung diseases characterized by the recruitment of blood neutrophils in the airways favoring the formation of a thick, mucoid or mucopurulent sputum as found in cystic fibrosis. | 2015-06-25 |
20150174194 | METHODS FOR TREATING LIVER TRANSPLANT RECIPIENTS - This application features interferon-free therapies for the prevention or treatment of HCV infection in liver transplant recipient. In one aspect, the treatment comprises administering a DAA combination to a liver transplant recipient after liver transplantation, wherein the DAA combination comprises Compound 1, ritonavir, Compound 2 and Compound 4. | 2015-06-25 |
20150174195 | METHODS FOR INCREASING AND MOBILIZING HEMATOPOIETIC STEM CELLS - A method is provided for increasing the number of hematopoietic stem cells in the bone marrow, increasing the mobilization of these cells to migrate from the bone marrow to the bloodstream and elsewhere, and increasing the number of differentiating hematopoietic stem cells in the bloodstream. | 2015-06-25 |